膜联蛋白A2是评估喉癌恶性进展的独立预后生物标志物。
Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer.
作者信息
Luo Shi, Xie Chubo, Wu Ping, He Jian, Tang Yaoyun, Xu Jing, Zhao Suping
机构信息
Department of Otorhinolaryngology Head and Neck Surgery, Key Laboratory of Otolaryngology Critical Diseases, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China.
出版信息
Exp Ther Med. 2017 Dec;14(6):6113-6118. doi: 10.3892/etm.2017.5298. Epub 2017 Oct 12.
Due to the lack of a definite diagnosis, a frequent recurrence rate and resistance to chemotherapy or radiotherapy, the clinical outcome for patients with advanced laryngeal cancer has not improved over the last decade. Annexin A2 is associated with the invasion and metastasis of cancer cells. In the present study, it was demonstrated using differential proteomics analysis that Annexin A2 is highly expressed in laryngeal carcinoma tissues and this was confirmed using immunohistochemistry, which demonstrated that the expression of Annexin A2 in laryngeal carcinoma tissues was significantly higher than in healthy adjacent tissue. In addition, its potential predictive value in the prognosis of patients with laryngeal carcinoma was evaluated. The results demonstrated that Annexin A2 expression was significantly associated with tumor size, lymph node metastasis, distant metastasis and clinical stage. In addition, higher Annexin A2 expression was associated with a poor prognosis of patients with laryngeal cancer. Thus, the results of the present study indicate that Annexin A2 expression is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer.
由于缺乏明确的诊断、频繁的复发率以及对化疗或放疗的耐药性，晚期喉癌患者的临床结局在过去十年中并未得到改善。膜联蛋白A2与癌细胞的侵袭和转移相关。在本研究中，通过差异蛋白质组学分析表明膜联蛋白A2在喉癌组织中高表达，免疫组织化学证实了这一点，其表明膜联蛋白A2在喉癌组织中的表达明显高于健康的邻近组织。此外，评估了其在喉癌患者预后中的潜在预测价值。结果表明，膜联蛋白A2表达与肿瘤大小、淋巴结转移、远处转移及临床分期显著相关。此外，膜联蛋白A2高表达与喉癌患者的不良预后相关。因此，本研究结果表明，膜联蛋白A2表达是评估喉癌恶性进展的独立预后生物标志物。
Zotero 插件